Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback